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open access aBackground: The Community Preventive Services Task Force recommends combined diet and
physical activity promotion programs for people at increased risk of type 2 diabetes, as evidence
continues to show that intensive lifestyle interventions are effective for overweight individuals with
prediabetes.
Purpose: To illustrate the potential clinical and economic beneﬁts of treating prediabetes with
lifestyle intervention to prevent or delay onset of type 2 diabetes and sequelae.
Methods: This 2014 analysis used a Markov model to simulate disease onset, medical expenditures,
economic outcomes, mortality, and quality of life for a nationally representative sample with
prediabetes from the 20032010 National Health and Nutrition Examination Survey. Modeled
scenarios used 10-year follow-up results from the lifestyle arm of the Diabetes Prevention Program
and Outcomes Study versus simulated natural history of disease.
Results: Over 10 years, estimated average cumulative gross economic beneﬁts of treating patients who
met diabetes screening criteria recommended by the ADA ($26,800) or USPSTF ($24,700) exceeded
average beneﬁts from treating the entire prediabetes population ($17,800). Estimated cumulative, gross
medical savings for these three populations averaged $10,400, $11,200, and $6,300, respectively.
Published estimates suggest that opportunistic screening for prediabetes is inexpensive, and lifestyle
intervention similar to the Diabetes Prevention Program can be achieved forr$2,300 over 10 years.
Conclusions: Lifestyle intervention among people with prediabetes produces long-term societal
beneﬁts that exceed anticipated intervention costs, especially among prediabetes patients that meet
the ADA and USPSTF screening guidelines.
(Am J Prev Med 2015;48(3):271–280) & 2015 American Journal of Preventive Medicine. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).IntroductionApproximately 86 million people in the U.S. haveprediabetes, a condition where blood glucoselevels are elevated but remain below the diabetic
threshold.1 These individuals are at high risk for devel-
oping type 2 diabetes, heart disease, and stroke, with
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Clinical trials demonstrate that counseling and treat-
ment can prevent diabetes or delay onset among high-
risk populations.6–9 Lifestyle intervention in the Diabetes
Prevention Program and Outcomes Study (DPPOS)
resulted in reduced body weight and hemoglobin A1c
(HbA1c) levels that persisted through 10-year follow-up.7
Screening for diabetes and prediabetes and subsequent
diagnosis are precursors to receiving counseling and
treatment. The American Diabetes Association (ADA)
recommends screening overweight, asymptomatic adults
with additional risk factors, and triennial screening for
adults aged Z45 years without risk factors.10 The U.S.
Preventive Services Task Force (USPSTF) 2008 guide-
lines recommend screening asymptomatic adults with
sustained hypertension, though draft new screeningvier Inc. This is an
mmons.org/licenses/by-nc-nd/3.0/).
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lines.11 ADA recommends screening for prediabetes;
USPSTF (2008 guidelines) does not, citing limited
evidence on long-term beneﬁts. Limited information
exists on screening cost effectiveness, although one study
concluded that prediabetes and diabetes screening and
subsequent intervention appear cost effective.3 This study
estimates the potential long-term health and economic
beneﬁts of lifestyle intervention among the total U.S.
prediabetes population and subsets meeting ADA and
USPSTF screening criteria.Methods
This 2014 analysis used a Markov-based microsimulation model
similar to those previously used to study health outcomes.12,13 The
approach simulated interactions between demographics; smoking
status; biometrics—BMI, systolic (SBP) and diastolic blood pres-
sure (DBP), total cholesterol, high-density lipoprotein cholesterol,
and HbA1c levels; incidence of disease and adverse health events;
and mortality (Figure 1). Health outcomes impacted annualFigure 1. Disease Prevention Microsimulation Model Overview.
Note: Arrows indicate linkages in the model. Risk factors (especially aging) af
used to model disease incidence. Presence of disease, and other factors suc
economic outcomes modeled. See Appendix (available online) for more det
CHF, congestive heart failure; CKD, chronic kidney disease; DBP, diastolic blo
ischemic heart disease; LVH, left ventricular hypertrophy; PVD, peripheral
pressure.medical costs, productivity (employment status, missed work days,
income, and disability payments), and quality of life. Modeled
scenarios used 10-year follow-up results from the lifestyle arm of
the DPPOS versus simulated natural disease history.14
The analyzed population, statistical analysis, and predictive equa-
tions are brieﬂy described in the following sections. The Appendix
(available online) provides additional detail on model design, data,
assumptions, methods, and validation, following guidelines published
by the International Society for Pharmacoeconomics and Outcomes
Research and Society for Medical Decision Making.15Study Population
The National Health and Nutrition Examination Survey
(NHANES) is a nationally representative sample of the non-
institutionalized population.16 The combined 20032010
NHANES contains 3,700 adults with prediabetes deﬁned by
6.4%ZHbA1cZ5.7%.10 Although other diagnostic tests (fasting
plasma glucose [FPG] and 2-hour oral glucose tolerance test
[OGTT]) can be used to determine prediabetes status, HbA1c was
used to model diabetes onset and is a risk factor in published
comorbidity prediction equations. Sensitivity analyses used bothfect annual change in biometrics. Risk factors (including biometrics) are
h as demographics, affects mortality risk, medical expenditures, and the
ail on the model.
od pressure; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; IHD,
vascular disease; QALY, quality-adjusted life year; SBP, systolic blood
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diabetes onset.
Individual proﬁles contained demographics (age, sex, race, and
Hispanic ethnicity), biometrics, current smoking status, and
presence of recognized risk factors and complications of diabetes
—hypertension, ischemic heart disease, congestive heart failure,
stroke, heart attack, renal failure, amputation, and blindness.17–19
This proﬁle created a starting point for simulating future health
outcomes.
Intervention and nonintervention scenarios were simulated for
three prediabetes populations: (1) all adults (n=3,700); (2) adults
satisfying ADA screening criteria (n=2,887)10; and (3) adults
satisfying USPSTF (2008 guidelines) screening criteria
(n¼1,621).11 Each simulation used 100,000 observations where
sample weights determined the probability a person was drawn
from the NHANES sample.
Simulating Health Outcomes, Mortality, and Quality
of Life
Each person’s current characteristics were used to predict next
year’s health outcomes, with this process repeated through 10
years or death. The intervention scenario assumed average HbA1c
and body weight declines observed during the DPPOS 10-year
follow-up; the nonintervention scenario assumed the natural
history of disease under current standards of care.14 Model
parameters and prediction equations came from the United
Kingdom Prospective Diabetes Study (UKPDS),19–23 Framingham
Heart Study,24–28 and published trials and observational studies.
Original research with NHANES ﬁlled in data gaps (Appendix,
available online).
Illustrating interdependence of clinical and disease outcomes,
the following sequence modeled annual change in risk factors and
outcomes:1.MaBody weight changed with age. The rate of change reﬂected the
average difference in BMI between subsequent ages in a cross-
sectional analysis of NHANES data, calculated separately by sex
and body weight category (BMIo25, 25rBMIo30,
BMIZ30). Validation found patterns similar to published
ﬁndings using longitudinal data.292. For people experiencing diabetes onset, rates of change in SBP,
HbA1c, and cholesterol were predicted using demographics
and BMI change with equations from the UKPDS Outcomes
Model.19 For people with prediabetes, annual changes in SBP,
DBP, total cholesterol, and high-density lipoprotein cholesterol
were modeled based on age and change in BMI. Annual change
in HbA1c was modeled based on age, BMI change, and total
cholesterol. The equations combined analysis of NHANES and
parameters from the literature.24,30,31 A meta-analysis of
clinical trials found that a 1-kg loss in excess body weight is
associated with a 1.05-mmHg reduction in SBP.30 To estimate
age-associated SBP changes, ordinary least squares regression
with NHANES data (separately for men and women) used SBP
as the dependent variable, age and age squared as explanatory
variables, and BMI as a control variable.3. Onset of diabetes and hypertension were modeled from HbA1c32
and SBP levels,33 respectively, using clinical guidelines.
4. Equations to predict incidence of atrial ﬁbrillation20,21; left
ventricular hypertrophy34; ischemic heart disease (IHD),rch 2015myocardial infarction (MI), congestive heart failure (CHF), and
stroke19,22,25; chronic kidney disease (CKD)23; and peripheral
vascular disease35 came from the literature for the prediabetes
population. For the diabetes population, the equations for
many of these conditions and amputation and blindness came
from the UKPDS Outcomes Model.195. Annual, event-based mortality rates for diabetes,19 IHD,22
CHF,36 MI,37 stroke,38 renal failure,23 and CKD39 came from
published equations and reﬂect mortality risk associated with
demographics, biometrics, smoking, and disease presence. All-
cause mortality rates were adjusted to remove cause-speciﬁc
mortality modeled separately.406. Estimates of reduced quality of life associated with obesity,
amputation, and renal failure were based on people with type 2
diabetes, whereas estimates for other conditions were based on
a nationally representative sample of adults.41,42
Simulating Medical Expenditures and Economic
Outcomes
All monetary estimates are in 2013 U.S. dollars and reﬂect present
values using a 3% discount rate. The relationship between annual
medical expenditures and patient characteristics was estimated
using a generalized linear model with gamma distribution and log
link, analyzing data from the 20062010 ﬁles (n=165,913) of the
Medical Expenditure Panel Survey (MEPS). Explanatory variables
were age group, sex, race, Hispanic ethnicity, insurance status,
body weight (overweight, obese), presence of modeled diseases,
and interaction terms for diabetes and modeled diseases (regres-
sion results shown in Appendix Exhibit 27, available online).
Estimates based on MEPS reﬂect average annual costs for those
living. End of life costs were based on published estimates.43
Estimated relationships between disease presence and economic
outcomes came from regression analysis of the linked 20082010
MEPS and National Health Interview Survey ﬁles. Explanatory
variables were the same as those described here. Economic
outcomes analyzed for the entire adult population in the linked
ﬁles were employed status (n¼25,296) and receiving Supplemental
Security Income for disability (n¼26,080)—both estimated with
logistic regression. Annual missed workdays were analyzed for the
employed population (n¼18,699) using negative binomial regres-
sion. Ordinary least squares regression with MEPS data
(n¼165,913) modeled household income (regression results pre-
sented in Appendix Exhibit 28, available online).
Results
The simulated sample is nationally representative of the
prediabetic population identiﬁable using HbA1c. In the
initial simulation year, 51% were women, and mean ages
were 54 years for men and 58 years for women (Table 1).
Those meeting USPSTF (2008 guidelines) criteria were
older, with higher BMI, and had greater prevalence of
cardiovascular disease relative to those meeting ADA
criteria and the total prediabetic population.
Under the nonintervention scenario, nearly one third
of the prediabetes population (32.5%) developed diabetes
within 10 years (Table 2). Mortality reached 33.9%, and
Table 1. Prediabetes Population Starting Year Characteristics
All prediabetes ADA identiﬁed USPSTF (2008) identiﬁed
Men Women Men Women Men Women
% 49.2 50.8 49.7 50.3 46.1 53.9
Mean
Age, y 53.9 58.1 55.0 58.9 59.3 63.4
BMI 30.0 30.1 31.0 31.5 31.3 30.9
Systolic blood pressure, mmHg 128.1 129.7 128.3 130.6 132.6 136.8
Diastolic blood pressure, mmHg 73.6 69.7 73.8 69.8 74.1 69.6
Cholesterol ratio 4.7 4.0 4.8 4.1 4.6 4.0
HbA1c, % 5.9 5.9 5.9 5.9 5.9 5.9
Disease prevalence, %
Congestive heart failure 3.4 2.3 4.3 2.7 6.3 4.3
History of myocardial infarction 7.3 2.9 9.2 3.3 12.1 4.9
History of stroke 3.3 4.4 3.7 4.7 6.5 7.5
Hypertension 50.7 55.1 40.8 38.9 100.0 100.0
Ischemic heart disease 11.2 6.6 14.0 7.9 19.2 11.8
Obesity 43.1 44.3 48.3 47.9 51.1 47.4
Note: Several risk factors and health states in the model are not available in the NHANES data used to create the starting year health proﬁle. These
conditions are modeled based on other patient characteristics—with some conditions modeled only among the population with simulated diabetes
onset. Modeled conditions include amputation, atrial ﬁbrillation, diabetic retinopathy, left ventricular hypertrophy, peripheral vascular disease, and
renal failure (to include chronic kidney disease and end stage renal disease).
ADA, American Diabetes Association; HbA1c, hemoglobin A1c; NHANES, National Health and Nutrition Examination Survey; USPSTF, U.S. Preventive
Services Task Force.
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reached 36.4%. Over 10 years, 15.7% developed CKD,
13.8% developed CHF, and 10.7% developed IHD. The
present value of gross medical expenditures over 10 years
averaged $73,900 per person ($90,200 per person living
at year 10).
Over 10 years, intervention reduced diabetes onset by
41%, CHF by 33%, IHD by 22%, and mortality by 20%
(Table 3). Cumulative medical expenditures per person
were $6,300 (9%) lower. Average nonmedical beneﬁts
were $11,500 higher—primarily from increased employ-
ment and household income. Absenteeism per worker
declined, but higher employment increased total missed
workdays. The present value of gross economic beneﬁts
of intervention averaged $17,800 ($16,100 using a 5%
discount rate, $21,000 using a 0% discount rate).
Among the prediabetes population, approximately
43% had undetected prediabetes but met ADA criteria
for diabetes screening, and 30% had undetected predia-
betes but met USPSTF criteria in 2010.44 Applied to the
2012 estimate of 86 million with prediabetes, this
suggests that potentially 2637 million case patients in
2012 could have been detected and enrolled in treatment.Without intervention, simulated diabetes onset over 10
years was 46.4% for the ADA-identiﬁed population and
44.3% for the USPSTF-identiﬁed population. Interven-
tion reduced average, 10-year cumulative medical costs
for the ADA-identiﬁed population by $10,400 ($12,000
$9,500 using a 0%5% discount rate) and for the
USPSTF-identiﬁed population by $11,200 ($12,800
$10,200) (Table 4).
If estimated beneﬁts were scaled to the entire predia-
betes population, these ﬁndings suggest that, over 10
years, the nation could potentially prevent more than
11.4 million cases of diabetes, avoid $539 billion in
medical costs, create $992 billion in nonmedical beneﬁts
(largely through 11 million additional years of employ-
ment), and gain nearly 30 million quality-adjusted life
years. Among the 37 million people with undiagnosed
prediabetes meeting ADA screening guidelines, inter-
vention could prevent 9.5 million diabetes cases with
economic beneﬁts of $991 billion.
A formal cost effectiveness analysis was outside the
scope of this study, but others have reported costs for
screening and treatment.45–47 The Healthy Living Part-
nerships to Prevent Diabetes (HELP PD) trial, whichwww.ajpmonline.org
Table 2. Cumulative Outcomes for Nationally Representative Sample of 100,000
Adults with Prediabetes (No Intervention Scenario)
2 Years 5 Years 10 Years
New disease cases, n
Diabetes 7,100 16,900 32,500
Ischemic heart disease 1,900 5,100 10,700
Congestive heart failure 2,600 6,700 13,800
Stroke 1,700 4,500 9,300
Heart attack 1,000 2,700 5,900
Renal failure 3,400 8,300 15,700
Amputation 10 50 140
Blindness 50 340 1,200
Medical expenditures ($ millions) 1,521 3,869 7,389
Medical expenditures/person still living 15,700 42,200 90,200
Nonmedical economic outcomes ($ millions) 8,763 19,489 31,909
Household income ($ millions) 9,137 20,346 33,372
Years of employment 104,850 243,210 421,810
Absenteeism (missed work days) 1,555,000 3,630,000 6,365,000
Absenteeism productivity loss ($ millions) 289 649 1,078
Supplemental Security Income ($ millions) 85 207 385
Mortality 5,000 14,800 33,900
Years of life 193,200 459,400 828,100
Quality-adjusted life years 150,430 353,960 628,450
Note: All dollar ﬁgures are present values in 2013 dollars, using a 3% discount rate. Numbers
might not sum to totals because of rounding.
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reported costs of $7.50 (2013 dollars) per test and 2.5
people screened for each identiﬁed prediabetes case.46
Opportunistic screening for prediabetes is relatively
inexpensive per person, although follow-up visits for
conﬁrmation and testing would increase detection costs.
DPP lifestyle intervention cost $3,770 (2013 dollars)
per participant.47 Subsequent lifestyle interventions have
achieved similar outcomes at lower treatment cost
through a different mix of medical and allied health
professionals, use of electronic media, and a less-
individualized approach. HELP PD costs were $850 per
participant over 2 years, including the costs for counselor
time, distribution of materials, a monthly newsletter, and
reminder calls and e-mails. Cost was $568 during the
intensive phase (Months 16), and $282 during the
maintenance phase (Months 724). Over 10 years (with
a 3% discount rate and attrition due to mortality), the
cost would be $2,300 per participant. The YMCA’s
Diabetes Prevention Program achieved short-termMarch 2015patient weight loss results similar to
HELP PD and the original DPP
study, but at service-delivery costs of
about $400 per person completing the
12-month program.45
Discussion
Lifestyle intervention among adults
with prediabetes can reduce body
weight, BP, and glycemic levels,6,45,47
although clinical trials of treatment
for prediabetes and early diabetes
stages have produced disappointing
results regarding impact on long-term
complications.5,48 Evidence suggests
that lifestyle interventions implemented
over a short period can still have long-
lasting, beneﬁcial, carryover effects on
type 2 diabetes incidence.49 Long-term
health beneﬁts are considered the true
measure of diabetes screening program
cost effectiveness.50 Although other
studies have reported the clinical bene-
ﬁts of lifestyle intervention, the primary
contribution of this study is translating
improvement in body weight and gly-
cemic levels into estimates of long-term
economic outcomes. There are three
key implications of this study.
First, the simulated economic ben-
eﬁts of treating prediabetes via life-
style intervention appear to faroutweigh intervention costs over the analyzed 10-year
period, with higher simulated beneﬁts among the pre-
diabetes population meeting ADA and USPSTF screen-
ing guidelines. Published estimates of opportunistic
screening costs ($18.50) and intervention costs (about
$2,300) are well below the simulated medical savings
($6,300$11,200) and total societal beneﬁts ($17,800
$26,800) per participant.
Second, the prediabetes population meeting ADA screen-
ing guidelines is younger and healthier than the population
meeting USPSTF (2008) guidelines. Over 10 years, average
medical savings from intervention were greater among the
USPSTF population, but societal economic beneﬁts were
greater among the ADA population. In 2010, approximately
14.9 million people with undetected prediabetes met ADA,
but not USPSTF, diabetes screening criteria, while 5.4
million met USPSTF, but not ADA, criteria.44 Preliminary
analysis of USPSTF’s new draft screening guidelines suggest
that the population detected with prediabetes is slightly
larger than the population detected under the ADA
Table 3. Cumulative Beneﬁts of Lifestyle Intervention for Nationally Representative Sample of 100,000 Adults with Prediabetes
Cumulative impact
Impact at year 10, %2 Years 5 Years 10 Years
New disease cases, n
Diabetes (2,800) (5,400) (13,300) (41)
Ischemic heart disease (280) (1,000) (2,300) (22)
Congestive heart failure (440) (1,700) (4,500) (33)
Stroke (380) (1,400) (3,400) (36)
Heart attack (180) (800) (2,100) (35)
Renal failure (60) (130) 0 0
Amputation (10) (30) (90) (63)
Blindness (20) (140) (510) (40)
Medical expenditures ($ millions) (69) (256) (630) (9)
Nonmedical economic outcomes ($ millions) 100 349 1,154 4
Household income ($ millions) 106 354 1,145 3
Years of employment 370 2,730 12,610 3
Absenteeism (missed work days) (29,000) (28,000) 67,000 1
Absenteeism productivity loss ($ millions) (5) (5) 9 1
Supplemental Security Income ($ millions) (0.4) (0.3) (0.5) 0
Mortality (410) (2,200) (6,800) (20)
Years of life 600 5,500 31,300 4
Total economic beneﬁts ($ millions) 169 604 1,784
Quality adjusted life years 2,530 9,120 34,720 6
Note: These numbers reﬂect a representative sample of 100,000 adults with prediabetes who participate in a lifestyle intervention program that achieves
10-year results similar to the Diabetes Prevention Program Outcomes Study. All dollar ﬁgures are present values in 2013 dollars, using a 3% discount rate.
Numbers might not sum to totals because of rounding. Numbers in parentheses reﬂect decreases relative to the nonintervention scenario.
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lifestyle intervention would be similar to results achieved
for an ADA-identiﬁed population.
Third, the cumulative beneﬁts of intervention continued
to grow over time. Among the ADA-identiﬁed population,
average gross economic beneﬁts were estimated to be $3,070,
$10,500, and $26,800 within 2, 5, and 10 years, respectively.
Screening and detection are precursors to receiving
counseling and treatment. USPSTF’s lack of recommenda-
tion on screening for prediabetes in their 2008 guidelines
stems from the paucity of published data on the value of
screening and treatment among the general diabetic pop-
ulation.51 Limited published evidence stems in part from the
challenges in using clinical trials as the main source of
evidence supporting interventions.52 Although clinical trials
are the gold standard of evidence-based medicine, they often
are of insufﬁcient size and duration to quantify outcomes
that take years to manifest. In this context, simulationmodeling has increased in importance to inform health
policy decisions.53–57
Yudkin and Montori58 argue that labeling and treating
people with prediabetes are associated with huge social and
economic burden. Our work suggests that relatively inex-
pensive diabetes lifestyle treatment programs can reduce
the social and economic burden among this population.Study Strengths and Limitations
This study used a microsimulation model that incorpo-
rates estimates from clinical trials and other sources to
track the pathways between a person’s characteristics,
biometrics, disease risk, onset, mortality, medical expen-
ditures, and workforce participation. Simulation allows
for better understanding of the pathways by which
reduction in body weight and glycemic levels attributed
to lifestyle intervention can prevent or delay onset ofwww.ajpmonline.org
Table 4. Potential Cumulative 10-year Beneﬁts if U.S. Population with Prediabetes Achieved DPPOS Lifestyle Intervention
Results
Total prediabetes
population
Meet ADA screening
criteria
Meet USPSTF (2008)
screening criteria
Estimated national cases with prediabetes in
2010 (millions)
86 37 26
Disease cases prevented, n
Diabetes (11,440,000) (9,480,000) (6,190,000)
Ischemic heart disease (1,980,000) (1,000,000) (890,000)
Congestive heart failure (3,870,000) (1,890,000) (1,460,000)
Disease incidence prevented, n
Stroke (2,920,000) (1,330,000) (1,070,000)
Heart attack (1,810,000) (890,000) (650,000)
Renal failure 0 (320,000) (230,000)
Amputation (80,000) (70,000) (50,000)
Blindness (440,000) (410,000) (340,000)
Total U.S. medical expenditures ($ billions) (539) (384) (292)
Medical expenditures per person, $ (6,300)
(7,300)a
(10,400)
(12,000)a
(11,200)
(12,800)a
Total U.S. non-medical beneﬁts ($ billions) 992 607 353
Nonmedical beneﬁts per person, $ 11,500
13,700a
16,400
19,300a
13,500
15,900a
Household income ($ billions) 985 603 349
Years of employment (millions) 10.8 7.0 4.2
Absenteeism (millions missed work days) 58 64 44
Productivity ($ billions) 8.0 9.7 6.8
Cost of Supplemental Security Income
($ billions)
(0.4) (5.9) (3.5)
Mortality (millions) (5.8) (3.0) (2.5)
Years of life (millions) 26.9 13.5 11.7
Total economic beneﬁts ($ billions) 1,531 991 644
Total economic beneﬁts per person, $ 17,800
21,000a
26,800
31,300a
24,700
28,700a
Quality-adjusted life years ($ millions) 25.1
29.9a
14.5
17.1a
10.6
12.5a
Note: All dollar and quality-adjusted life year ﬁgures are present values in 2013 dollars and use a 3% discount rate.
aIndicates undiscounted estimates. Numbers might not sum to totals because of rounding.
ADA, American Diabetes Association; DPPOS, Diabetes Prevention Program Outcomes Study; USPSTF, U.S. Preventive Services Task Force.
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isons across different populations.
One limitation is the lack of a single longitudinal data
source covering a sufﬁcient time period and of sufﬁcient
size to quantify disease onset and the relationship between
other patient characteristics. Therefore, data were used
from multiple sources, including UKPDS data collectedMarch 2015from a population outside the U.S. A second limitation is
the use of cross-sectional data for estimating change in
BMI and BP associated with aging. Validation activities
reported that the model’s predictive equations produced
outcomes consistent with aggregate published estimates
based on longitudinal data. A third limitation is that some
predictive equations for the prediabetic population are
Dall et al / Am J Prev Med 2015;48(3):271–280278based on analyses of a nondiabetic population, which
likely understates disease incidence under both the
intervention and nonintervention scenarios.
A fourth limitation is that some older data sources were
used (e.g., Framingham and UKPDS), and standards of
care such as statin use have evolved over time. Data from
the Look Action for Health in Diabetes (AHEAD) trial
and other studies report that statin use has increased over
time and is associated with decreased risk of adverse
cardiovascular disease (CVD) events, and that after
controlling for cholesterol levels, the impact of body
weight loss on CVD outcomes largely disappears.59–61
The model disease risk equations reﬂect that absolute
probability risk for CVD and other adverse events are
generally lower today compared to earlier years.
A ﬁfth limitation is using HbA1c to identify the
simulated population and model diabetes onset. Although
HbA1c is commonly used for diagnosis, trials often use
OGTT owing to sensitivity concerns. Prediabetic adults
identiﬁed by HbA1c, compared to OGTT, are more likely
to be non-Hispanic but have similar age and sex
distribution.62 Prediabetic adults identiﬁed by HbA1c,
FPG, and OGTT also differ in risk for diabetes and
cardiovascular disease—although the association between
test type and risk may be partially explained by the other
patient characteristics captured in our model.10 Explor-
atory analysis using HbA1c and FPG, but not OGTT
because of data limitations, suggests that using HbA1c
and FPG, rather than HbA1c alone, to identify the
simulation population andmodel diabetes onset increased
estimated medical savings from intervention by 4%.
Excess body weight increases risk for various types of
cancer, musculoskeletal problems, respiratory problems,
and other health issues omitted from this analysis.63 The
estimated beneﬁts of weight loss from lifestyle intervention
are conservative with respect to these omitted conditions.
Despite these limitations, validation activities suggest a
robust model. Simulated annual transition rates to diabetes
absence intervention (5.3%7.6%) for the population
meeting ADA and USPSTF screening criteria are consistent
with rates (5%10%) reported elsewhere.64 Validation
activities found that predicted incidence of cardiovascular
events matched well against recent published data.
Sensitivity analysis suggests medical expenditures are
most sensitive to HbA1c parameters and assumptions,
whereas mortality is most sensitive to CHF assumptions.
Excluding HbA1c, varying key modeled parameters by
50% in either direction resulted in maximum deviations
from baseline estimates of 4.5%, 10.9%, and 18.8%,
respectively, for cumulative 10-year diabetes incidence,
medical expenditures, and mortality. This suggests that
model results are robust to changes in input assumptions
and parameters.Conclusions
Ninety percent of people with prediabetes are undiag-
nosed, underscoring the need for a paradigm shift in
screening.65,66 This study highlights the value of treating
people with prediabetes. Total simulated economic
beneﬁts of lifestyle intervention averaged $26,800 and
$24,700, respectively, for people with prediabetes meet-
ing ADA and 2008 USPSTF screening criteria. Published
studies suggest that such interventions could be achieved
with investments of r$2,300.45–47
Among the estimated 37 million people with unde-
tected prediabetes meeting ADA screening criteria,
intervention could potentially prevent 9.5 million dia-
betes cases with gross national economic beneﬁts of $911
billion over 10 years. By contrast, among 26 million
people with undetected prediabetes meeting USPSTF
screening criteria, intervention could prevent 6.2 million
diabetes cases over 10 years with national economic
beneﬁts of $644 billion. These ﬁndings illustrate the
potential large economic beneﬁts of overall screening and
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